Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

53 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-14

Study Completion Date

2020-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to evaluate the change of neutrophil to lymphocyte ratio (NLR) after 6-week treatment of immune checkpoint inhibitors (ICIs) with or without immunomodulatory drugs and recognize the effect of post-treatment NLR and overall survival in advanced lung cancer patients by retrospective review.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prognostic Correlation Between the Ratio of the Neutrophil Ratio to the Ratio of CD4+/CD8+ T Cells in Patients With Advanced Non-small Cell Lung Cancer NSCLC) Undergoing Immunotherapy Combined With Chemotherapy

NCT06954259

NSCLC (Advanced Non-small Cell Lung Cancer)

ACTIVE_NOT_RECRUITING

irAE Prediction of Anti-PD-1/L1 in Lung Cancer

NCT05288569

Immune Checkpoint Inhibitors Lung Cancer

UNKNOWN

Care Needs in Lung Cancer Patients Receiving Immunotherapy

NCT06433206

Lung Cancer, Immunotherapy, Quality of Life, Symptom Severity, Care Needs

RECRUITING

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

NCT05415358

Lung Cancer, Nonsmall Cell

ACTIVE_NOT_RECRUITING

Study of Changes of Lymphocyte Subsets in Chemotherapy Course of Patients With Non-small Cell Lung Cancer

NCT02202655

Non-small Cell Lung Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In recent years, the therapeutic strategies for lung cancer have been enriched with small molecular targeted therapy and immunotherapy. In this retrospective study, we will observe the change in NLR and explore its possible association with survival among advanced lung cancer patients receiving Immune checkpoint inhibitors (ICIs) with and without such immuno-modulator, Astragalus Polysaccharide Injection. It can be used to understand the relationship between NLR values and the survival rate of lung cancer patients after ICIs treatment. Physicians can refer to this result to give patients the suitable treatment recommendations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1：ICI treatment with immunomodulator

Lung cancer patients received immunological checkpoint inhibitors (ICIs) and any immunomodulatory drugs.

No interventions assigned to this group

Cohort 2：ICI treatment without immunomodulator

Lung cancer patients received immunological checkpoint inhibitors (ICIs).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 20 years and older.
* Patients who have been given a diagnosis of lung cancer.
* Previously advanced lung cancer patients first treated with ICIs from Oct 1, 2015 to Oct 31, 2019.

Exclusion Criteria

* Patients who have no hematological laboratory data available at baseline (within 3 days prior to ICI treatment) and the 6th week (± 2 weeks) after ICI treatment initiation.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No